Maxcyte
MXCT
Maxcyte (MXCT) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Craig-Hallum | Maintained | Buy | $5.00 from $7.00 | Mar 25, 2026 |
| BTIG | Downgraded | Buy → Neutral | — | Aug 11, 2025 |
| William Blair | Downgraded | Outperform → Market Perform | — | Aug 7, 2025 |
| Stephens & Co. | Initiated Coverage | Overweight | $6.00 | Jul 22, 2025 |
| Stifel | Maintained | Buy | $9.00 from $11.00 | Mar 12, 2025 |
| Stephens & Co. | Maintained | Overweight | $11.00 | Apr 23, 2024 |
| BTIG | Maintained | Buy | $8.00 from $10.00 | Mar 13, 2024 |
| Stephens & Co. | Maintained | Overweight | $11.00 | Mar 13, 2024 |
| Craig-Hallum | Initiated Coverage | Buy | $7.00 | Nov 29, 2023 |
| Stephens & Co. | Maintained | Overweight | $12.00 | Oct 5, 2023 |
Frequently asked questions
What is the latest analyst rating on MXCT?
On Mar 25, 2026, Craig-Hallum maintained Maxcyte at Buy with a price target of $5.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.